Sunesis Pharmaceuticals Inc. (SNSS) Shares Up 3.7%
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) shot up 3.7% during trading on Friday . The company traded as high as $4.52 and last traded at $4.46, with a volume of 238,767 shares trading hands. The stock had previously closed at $4.30.
A number of research firms have commented on SNSS. Cowen and Company restated a “market perform” rating on shares of Sunesis Pharmaceuticals in a research report on Friday, July 29th. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 7th. Cantor Fitzgerald restated a “buy” rating on shares of Sunesis Pharmaceuticals in a research report on Monday. Finally, Wells Fargo & Co. upgraded Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, July 29th.
The firm’s 50 day moving average price is $4.44 and its 200 day moving average price is $3.55. The stock’s market capitalization is $64.68 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/16/sunesis-pharmaceuticals-inc-snss-shares-up-3-7.html
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Friday, July 29th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.02. The firm earned $0.60 million during the quarter, compared to analyst estimates of $0.70 million. Sunesis Pharmaceuticals had a negative return on equity of 806.43% and a negative net margin of 1,503.34%. The business’s revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.15) EPS. Equities analysts predict that Sunesis Pharmaceuticals Inc. will post ($2.64) EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in SNSS. First Eagle Investment Management LLC bought a new stake in shares of Sunesis Pharmaceuticals during the second quarter worth approximately $822,000. Vanguard Group Inc. boosted its stake in shares of Sunesis Pharmaceuticals by 0.9% in the second quarter. Vanguard Group Inc. now owns 2,499,581 shares of the biopharmaceutical company’s stock worth $1,369,000 after buying an additional 21,209 shares during the period. Finally, BVF Inc. IL boosted its stake in shares of Sunesis Pharmaceuticals by 0.8% in the first quarter. BVF Inc. IL now owns 4,813,294 shares of the biopharmaceutical company’s stock worth $2,599,000 after buying an additional 35,913 shares during the period. Institutional investors and hedge funds own 49.32% of the company’s stock.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.